Related Experiment Video
Updated: Mar 19, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
13.0K
Immunological treatment of multiple sclerosis
Martin Diebold1, Tobias Derfuss1
1Departments of Neurology and Biomedicine, University Hospital Basel, Switzerland.
Seminars in Hematology
|June 18, 2016
Summary
Recent advances offer new multiple sclerosis (MS) treatments, including novel immunomodulatory drugs and monoclonal antibodies. This review discusses current options and future directions for managing relapsing-remitting MS.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) treatment has evolved significantly since its initial description.
- The mid-1990s marked a turning point with the introduction of immunomodulatory drugs.
- The last decade has seen rapid advancements in therapies for relapsing-remitting MS.
Purpose of the Study:
- To review currently available treatment options for multiple sclerosis.
- To provide an outlook on emerging therapies in the near future.
Main Methods:
- Review of novel treatment options for relapsing-remitting MS.
- Discussion of immunomodulatory drugs and monoclonal antibodies.
- Analysis of drug mechanisms, including lymphocyte inhibition, depletion, and cytokine receptor blockade.
Main Results:
- Several novel treatments are now available for relapsing-remitting MS.
- These include natalizumab, alemtuzumab, daclizumab, teriflunomide, fingolimod, and dimethylfumarate.
- These therapies target various pathways, including lymphocyte migration, proliferation, and immune signaling.
Conclusions:
- The treatment landscape for MS has been transformed by recent therapeutic innovations.
- Current options offer diverse mechanisms for managing relapsing-remitting MS.
- Future research will likely yield further advancements in MS management.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
653
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
653
01:24T Cell Types and Functions
3.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.1K
01:29Autoimmune Disorders
2.1K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
2.1K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
716
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
716